<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Patient evidence Archives - Myeloma Patients Europe</title>
	<atom:link href="https://www.mpeurope.org/category/patient-evidence/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.mpeurope.org/category/patient-evidence/</link>
	<description></description>
	<lastBuildDate>Wed, 02 Sep 2026 14:05:56 +0000</lastBuildDate>
	<language>en-GB</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.5</generator>

<image>
	<url>https://www.mpeurope.org/wp-content/uploads/2023/07/logo_MPE-fav-1-150x150.png</url>
	<title>Patient evidence Archives - Myeloma Patients Europe</title>
	<link>https://www.mpeurope.org/category/patient-evidence/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>A young patient’s experience of induced menopause after myeloma treatment</title>
		<link>https://www.mpeurope.org/a-young-patients-experience-of-induced-menopause-after-myeloma-treatment/</link>
					<comments>https://www.mpeurope.org/a-young-patients-experience-of-induced-menopause-after-myeloma-treatment/#respond</comments>
		
		<dc:creator><![CDATA[Adam Davenport]]></dc:creator>
		<pubDate>Wed, 02 Sep 2026 07:15:40 +0000</pubDate>
				<category><![CDATA[MPE]]></category>
		<category><![CDATA[Patient evidence]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/?p=116811</guid>

					<description><![CDATA[<p>As part of our September European Young Myeloma Patients Group (EYMPG) meeting on Induced Menopause and Sexual Health in young myeloma patients, Filipa Lopes has shared her personal experience of treatment induced menopause. She was diagnosed with myeloma at the age of 29 and hopes her story encourages other young patients to seek support and&#8230;</p>
<p>The post <a href="https://www.mpeurope.org/a-young-patients-experience-of-induced-menopause-after-myeloma-treatment/">A young patient’s experience of induced menopause after myeloma treatment</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="116811" class="elementor elementor-116811" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-adb9cc8 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="adb9cc8" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-75fe29e" data-id="75fe29e" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-5f5d42e elementor-widget elementor-widget-text-editor" data-id="5f5d42e" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>As part of our September European Young Myeloma Patients Group (EYMPG) meeting on <strong>Induced Menopause and Sexual Health</strong> <strong>in young myeloma patients</strong>, <strong>Filipa Lopes</strong> has shared her personal experience of treatment induced menopause.</p><p>She was diagnosed with myeloma at the age of 29 and hopes her story encourages other young patients to seek support and know they are not alone.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-2e121ec elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="2e121ec" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-d0e88aa" data-id="d0e88aa" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-ee712bc elementor-widget-divider--view-line elementor-widget elementor-widget-divider" data-id="ee712bc" data-element_type="widget" data-e-type="widget" data-widget_type="divider.default">
				<div class="elementor-widget-container">
							<div class="elementor-divider">
			<span class="elementor-divider-separator">
						</span>
		</div>
						</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-b81be16 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="b81be16" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-78933a5" data-id="78933a5" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-a3d6048 elementor-widget elementor-widget-heading" data-id="a3d6048" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">Filipa`s Story</h4>				</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-a4fde48 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="a4fde48" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-38cefe5" data-id="38cefe5" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-df539e4 elementor-widget elementor-widget-text-editor" data-id="df539e4" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>Hi everyone,</p><p>I was diagnosed with myeloma at 29 years old, and I would like to share my experience with medically induced menopause with all of you.</p><p>Before my stem cell transplant, my doctors explained the different side effects I could experience from the high-dose chemotherapy. However, it wasn’t until I actually experienced them myself that I truly understood what induced menopause meant and the impact it could have on my body, my mind and my self-esteem.</p><p>The first sign was the loss of my period. I had my last cycle a few days after my transplant and that was the last time I saw it. Then came the sudden hot flashes and night sweats, vaginal dryness that led to pain during sex, weight gain, difficulty concentrating and mood swings. It felt overwhelming. I was already trying to cope with this diagnosis and everything that came with it, and suddenly I was also dealing with changes that made me feel like I no longer recognised my own body. Slowly, I also started to realise that becoming a mother after all of this would be extremely difficult, even though I had frozen my eggs before treatment. That was another very painful thing to process.</p><p>When I first shared what I was experiencing with my doctor, I felt dismissed and ignored. And this is really difficult to talk about. But I was so uncomfortable and so unhappy with the way I was feeling that I decided to share all my symptoms again at my next appointment. I will never forget what he told me: “Young lady, it was us who did that terrible thing to you…”</p><p>Although I understood that the treatment had caused these changes, what I needed at that moment was empathy and support. Instead, there was no advice or discussion about possible ways of managing my symptoms. It felt as though menopause was something I simply had to accept and put up with, and that eventually it would all go away. But I was struggling a lot.</p><p>What really helped me during that period was reaching out to my support network. I had several sessions with my psychologist and most importantly, I reached out to other people who had gone through similar experiences. In particular, I had a friend my age who had been diagnosed with breast cancer and was going through many of the same changes. We shared our struggles, talked openly about things that were sometimes difficult to say out loud and exchanged tips on how to cope with them. Knowing that I wasn’t alone made a huge difference.</p><p>Four years have now passed, and I am doing well. Looking back, I wish I had known that I didn’t have to simply accept all of these symptoms as something I had to endure.</p><p>So, my advice to all of you is: if you are struggling, please speak up and ask for help. You don&#8217;t have to suffer in silence just because something is a consequence of cancer treatment. Talk to your medical team, ask about options for managing your symptoms, and don’t be afraid to seek a second opinion if you feel that your concerns are not being heard. Reach out to your family and friends, psychologists, patient advocates or patient organisations. And, if possible, connect with other young people who have gone through something similar.</p><p>You deserve to be heard, supported and cared for.</p><p>Stay strong</p>								</div>
				</div>
				<div class="elementor-element elementor-element-92fb323 elementor-widget-divider--view-line elementor-widget elementor-widget-divider" data-id="92fb323" data-element_type="widget" data-e-type="widget" data-widget_type="divider.default">
				<div class="elementor-widget-container">
							<div class="elementor-divider">
			<span class="elementor-divider-separator">
						</span>
		</div>
						</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-be8a03a elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="be8a03a" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-2e185a4" data-id="2e185a4" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-96cc87e elementor-widget elementor-widget-text-editor" data-id="96cc87e" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><strong>Need support or want to learn more?</strong></p><p>Join our upcoming EYMPG meeting on <strong>17 September 2026</strong> about <strong>Induced menopause and sexual health in young myeloma patients.</strong></p><p>Register here: <a href="https://forms.cloud.microsoft/e/ZSFF1cRJdi">EYMPG &#8211; Online Meeting Registration Form – Fill in form</a></p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://www.mpeurope.org/a-young-patients-experience-of-induced-menopause-after-myeloma-treatment/">A young patient’s experience of induced menopause after myeloma treatment</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/a-young-patients-experience-of-induced-menopause-after-myeloma-treatment/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Shape your myeloma care: New MPE research highlights the power of shared decision-making in myeloma care</title>
		<link>https://www.mpeurope.org/shape-your-myeloma-care-new-mpe-research-highlights-the-power-of-shared-decision-making-in-myeloma-care/</link>
					<comments>https://www.mpeurope.org/shape-your-myeloma-care-new-mpe-research-highlights-the-power-of-shared-decision-making-in-myeloma-care/#respond</comments>
		
		<dc:creator><![CDATA[Adam Davenport]]></dc:creator>
		<pubDate>Tue, 02 Sep 2025 15:49:57 +0000</pubDate>
				<category><![CDATA[MPE]]></category>
		<category><![CDATA[Myeloma]]></category>
		<category><![CDATA[Patient evidence]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/?p=112458</guid>

					<description><![CDATA[<p>Myeloma is a form of blood cancer. At diagnosis, and at each relapse, myeloma patients are confronted with complex treatment and care decisions that may feel overwhelming. What are my options? What are the side effects? How will it affect my quality of life? The questions you have regarding your care choices are deeply personal&#8230;</p>
<p>The post <a href="https://www.mpeurope.org/shape-your-myeloma-care-new-mpe-research-highlights-the-power-of-shared-decision-making-in-myeloma-care/">Shape your myeloma care: New MPE research highlights the power of shared decision-making in myeloma care</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="112458" class="elementor elementor-112458" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-aec3656 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="aec3656" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-be4a826" data-id="be4a826" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap">
							</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-4b476e5 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="4b476e5" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-d3e3e2b" data-id="d3e3e2b" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-7cd3091 elementor-widget elementor-widget-text-editor" data-id="7cd3091" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><span data-contrast="auto">Myeloma is a form of blood cancer. At diagnosis, and at each relapse, myeloma patients are confronted with complex treatment and care decisions that may feel overwhelming. What are my options? What are the side effects? How will it affect my quality of life? The questions you have regarding your care choices are deeply personal and important for healthcare professionals to know when discussing your care. Including what is important to you can help to shape your treatments and care to better fit your needs and preferences. </span><span data-ccp-props="{}"> </span></p><p><span data-contrast="auto">Given how important this topic is, we&#8217;re excited to share our new research that sheds light on how decision-making currently takes place in myeloma treatment and care across Europe and recommends how to improve things for patients.</span><span data-ccp-props="{}"> </span></p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-03ebebd elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="03ebebd" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-cb50354" data-id="cb50354" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-c90294f elementor-widget elementor-widget-heading" data-id="c90294f" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">What is shared decision-making?</h4>				</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-b414a31 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="b414a31" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-89c2f5a" data-id="89c2f5a" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-6fef9a3 elementor-widget elementor-widget-text-editor" data-id="6fef9a3" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><span data-contrast="auto">Shared decision-making is exactly what it sounds like: a process where you and your healthcare team work together to make important decisions about your treatment and care. It combines your health professionals&#8217; medical expertise with your values, concerns, lifestyle, and personal goals.</span><span data-ccp-props="{}"> </span></p><p><span data-contrast="auto">Think of it as a partnership where your voice helps to shape the path forward for your treatment and care. You can be involved in your treatment and care decisions, as much or as little as you want! </span><span data-ccp-props="{}"> </span></p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-adb986e elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="adb986e" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-664b24f" data-id="664b24f" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-19c99da elementor-widget elementor-widget-heading" data-id="19c99da" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">What our research showed</h4>				</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-919a5a5 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="919a5a5" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-66 elementor-top-column elementor-element elementor-element-0825e95" data-id="0825e95" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-c4fd54a elementor-widget elementor-widget-text-editor" data-id="c4fd54a" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><span data-contrast="auto">More than half (57%) of myeloma patients had never heard of shared decision-making. Even when patients had heard of shared decision-making, many reported that it did not happen consistently in practice:</span><span data-ccp-props="{}"> </span><span data-ccp-props="{}"> </span></p><ul><li aria-setsize="-1" data-leveltext="" data-font="Symbol" data-listid="1" data-list-defn-props="{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}" data-aria-posinset="1" data-aria-level="1"><span data-contrast="auto">patients weren&#8217;t always asked if they understood their treatment options or asked how they preferred to receive information</span><span data-ccp-props="{}"> </span></li></ul><ul><li aria-setsize="-1" data-leveltext="" data-font="Symbol" data-listid="1" data-list-defn-props="{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}" data-aria-posinset="2" data-aria-level="1"><span data-contrast="auto">many didn&#8217;t get the opportunity to share their fears, concerns, or preferences</span><span data-ccp-props="{}"> </span></li></ul><ul><li aria-setsize="-1" data-leveltext="" data-font="Symbol" data-listid="1" data-list-defn-props="{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}" data-aria-posinset="3" data-aria-level="1"><span data-contrast="auto">discussion of treatment alternatives was often limited</span><span data-ccp-props="{}"> <br /><br /></span><span data-contrast="auto">Our research also found that time constraints in hospital appointments, emotional overwhelm for patients and communication challenges were amongst the biggest barriers to shared decision-making in practice.</span><span data-ccp-props="{}"> </span></li></ul>								</div>
				</div>
				<div class="elementor-element elementor-element-332b9b7 elementor-widget elementor-widget-spacer" data-id="332b9b7" data-element_type="widget" data-e-type="widget" data-widget_type="spacer.default">
				<div class="elementor-widget-container">
							<div class="elementor-spacer">
			<div class="elementor-spacer-inner"></div>
		</div>
						</div>
				</div>
				<div class="elementor-element elementor-element-0317a60 elementor-widget elementor-widget-text-editor" data-id="0317a60" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><span class="TextRun SCXW35569514 BCX8" lang="EN-US" xml:lang="EN-US" data-contrast="auto"><span class="NormalTextRun SCXW35569514 BCX8">Find out mo</span><span class="NormalTextRun SCXW35569514 BCX8">re about our research</span><span class="NormalTextRun SCXW35569514 BCX8">,</span><span class="NormalTextRun SCXW35569514 BCX8"> and our recom</span><span class="NormalTextRun SCXW35569514 BCX8">m</span><span class="NormalTextRun SCXW35569514 BCX8">endations </span><span class="NormalTextRun SCXW35569514 BCX8">for improvements in treatment and care decision</span><span class="NormalTextRun SCXW35569514 BCX8">-making</span><span class="NormalTextRun SCXW35569514 BCX8">,</span> <span class="NormalTextRun SCXW35569514 BCX8">in our</span><span class="NormalTextRun SCXW35569514 BCX8"> research summary below.</span></span><span class="EOP SCXW35569514 BCX8" data-ccp-props="{}"> </span></p>								</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-7aa98a5" data-id="7aa98a5" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-b6175fb elementor-widget elementor-widget-image" data-id="b6175fb" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
																<a href="https://www.mpeurope.org/wp-content/uploads/2025/09/MPE-shared-decision-making-report.pdf" target="_blank">
							<img fetchpriority="high" decoding="async" width="213" height="300" src="https://www.mpeurope.org/wp-content/uploads/2025/09/Screenshot-2025-09-02-144309-213x300.png" class="attachment-medium size-medium wp-image-112453" alt="Screenshot 2025 09 02 144309" srcset="https://www.mpeurope.org/wp-content/uploads/2025/09/Screenshot-2025-09-02-144309-213x300.png 213w, https://www.mpeurope.org/wp-content/uploads/2025/09/Screenshot-2025-09-02-144309.png 538w" sizes="(max-width: 213px) 100vw, 213px" />								</a>
															</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-7d6ae63 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="7d6ae63" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-fb582d4" data-id="fb582d4" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-6be5126 elementor-align-center elementor-widget elementor-widget-button" data-id="6be5126" data-element_type="widget" data-e-type="widget" data-widget_type="button.default">
				<div class="elementor-widget-container">
									<div class="elementor-button-wrapper">
					<a class="elementor-button elementor-button-link elementor-size-sm" href="https://www.mpeurope.org/what-we-do/research/patient-evidence/shared-decision-making-in-myeloma-what-do-health-care-professionals-working-in-myeloma-need-to-know-from-a-patient-perspective/">
						<span class="elementor-button-content-wrapper">
									<span class="elementor-button-text">Find out more</span>
					</span>
					</a>
				</div>
								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://www.mpeurope.org/shape-your-myeloma-care-new-mpe-research-highlights-the-power-of-shared-decision-making-in-myeloma-care/">Shape your myeloma care: New MPE research highlights the power of shared decision-making in myeloma care</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/shape-your-myeloma-care-new-mpe-research-highlights-the-power-of-shared-decision-making-in-myeloma-care/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Research Grant Application – Shared-Decision Making in Myeloma</title>
		<link>https://www.mpeurope.org/research-grant-application-shared-decision-making-in-myeloma/</link>
					<comments>https://www.mpeurope.org/research-grant-application-shared-decision-making-in-myeloma/#respond</comments>
		
		<dc:creator><![CDATA[Ana Vallejo]]></dc:creator>
		<pubDate>Mon, 11 Oct 2021 07:13:18 +0000</pubDate>
				<category><![CDATA[MPE]]></category>
		<category><![CDATA[Myeloma]]></category>
		<category><![CDATA[Patient evidence]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/research-grant-application-shared-decision-making-in-myeloma/</guid>

					<description><![CDATA[<p>Myeloma Patients Europe (MPE) is seeking research grant applications, for funding of up to 100k €, on a project exploring shared-decision making in myeloma. If you are interested, please read the information below and complete the following application form.  Deadline for submission is 3 pm CET on Friday 5th of November 2021 &#160; About the project&#8230;</p>
<p>The post <a href="https://www.mpeurope.org/research-grant-application-shared-decision-making-in-myeloma/">Research Grant Application – Shared-Decision Making in Myeloma</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Myeloma Patients Europe (MPE) is seeking research grant applications, for funding of up to 100k €, on a project exploring shared-decision making in myeloma.</p>
<p>If you are interested, please read the information below and complete the following <a href="https://www.mpeurope.org/wp-content/uploads/2021/10/Application-Form-Shared-Decision-Making_ok.pdf" target="_blank" rel="noopener">application form.</a>  <strong>Deadline for submission is 3 pm CET on Friday 5th of November 2021</strong></p>
<p>&nbsp;</p>
<p><span id="more-5731"></span></p>
<h5><strong>About the project</strong></h5>
<p>At MPE, we want to ensure that myeloma patients are as informed as possible when making decisions about their treatment. Evidence suggests that personal factors and preferences are influential in determining how patients arrive at treatment decisions. High quality information and support is also part of this decision making process. However, less is known about how patient information is actually used and how treatment decisions are made in practice, particularly across Eastern and Southern Europe.</p>
<p>This project aims to develop our understanding of information and shared decision making in myeloma. The project is about understanding, from a patient perspective, what health care professionals need to know. How do patients with myeloma and their families want to be involved in treatment decision making? What would help? What is working? Are there any examples of good practice which could be modelled and disseminated across Europe?</p>
<p>&nbsp;</p>
<h5><strong>Who we are looking for</strong></h5>
<p>MPE have funding of up to 100k€ for a 12-month project examining shared decision making We are looking for researchers to run the project as a university partner.</p>
<p>MPE will support patient engagement, recruitment, and any translations needed as part of the project. A steering group made up of patients, health care professionals, and researchers will be set up to guide and support the project.</p>
<p>&nbsp;</p>
<h5><strong>Further information</strong></h5>
<p>If you would like an informal discussion about the project, funding, or would like more details please contact Dr Jayne Galinsky, the MPE Head of Patient Evidence at <a href="mailto:galinsky@mpeurope.org">galinsky@mpeurope.org</a>.</p>
<p>The post <a href="https://www.mpeurope.org/research-grant-application-shared-decision-making-in-myeloma/">Research Grant Application – Shared-Decision Making in Myeloma</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/research-grant-application-shared-decision-making-in-myeloma/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Impact of the COVID-19 pandemic on the healthcare and lives of myeloma or AL amyloidosis patients and their caregivers</title>
		<link>https://www.mpeurope.org/impact-of-the-covid-19-pandemic-on-the-healthcare-and-lives-of-myeloma-or-al-amyloidosis-patients-and-their-caregivers/</link>
					<comments>https://www.mpeurope.org/impact-of-the-covid-19-pandemic-on-the-healthcare-and-lives-of-myeloma-or-al-amyloidosis-patients-and-their-caregivers/#respond</comments>
		
		<dc:creator><![CDATA[Ana Vallejo]]></dc:creator>
		<pubDate>Mon, 21 Jun 2021 10:08:58 +0000</pubDate>
				<category><![CDATA[AL amyloidosis]]></category>
		<category><![CDATA[MPE]]></category>
		<category><![CDATA[Myeloma]]></category>
		<category><![CDATA[Patient evidence]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/impact-of-the-covid-19-pandemic-on-the-healthcare-and-lives-of-myeloma-or-al-amyloidosis-patients-and-their-caregivers/</guid>

					<description><![CDATA[<p>The post <a href="https://www.mpeurope.org/impact-of-the-covid-19-pandemic-on-the-healthcare-and-lives-of-myeloma-or-al-amyloidosis-patients-and-their-caregivers/">Impact of the COVID-19 pandemic on the healthcare and lives of myeloma or AL amyloidosis patients and their caregivers</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>&nbsp;</p>
<p>In early 2020, we began to hear about a virus called <a href="https://www.mpeurope.org/qas/sars-cov-2-covid-19-vaccination-for-myeloma-patients/" target="_blank" rel="noopener"><strong>SARS-CoV-2 (COVID- 19).</strong></a> No one could imagine that this virus would result in a global pandemic with huge changes in our daily life and, most important, in our healthcare.<span id="more-5278"></span></p>
<p>&nbsp;</p>
<p>As the COVID-19 pandemic unfolded last year, Myeloma Patients Europe (MPE) became aware that the pandemic, and the restrictions imposed, were impacting the healthcare and lives of people with myeloma and AL amyloidosis, and their caregivers. Through our COVID-19 Outreach Workstream, and as part of our mission to provide education, information, and support to members and to advocate at European, national, and local levels, MPE began research to learn more about the effects of COVID-19 on the patient community.</p>
<p>&nbsp;</p>
<p>MPE has published a report summarising the results of a series of semi-structured focus groups conducted to collect personal experiences and broader insights from patients and caregivers.</p>
<p>&nbsp;</p>
<p><em>“This report provides insights into the patient and carer experience during COVID-19, its impact on diagnosis and treatment, effects on quality of life and psychosocial needs, and prompt access to vaccines, or lack thereof. The findings from this report can help identify potential needs of myeloma and AL amyloidosis patients, existing gaps in knowledge and services, and inequalities in access, which will be used to support MPE’s ongoing efforts to advocate for improved treatment, care, and access for the European patient community”</em>, says <strong>Ananda Plate, CEO of MPE.</strong></p>
<p>&nbsp;</p>
<p><a href="https://www.mpeurope.org/wp-content/uploads/2024/04/COVID-19-report-2021_web-1.pdf" target="_blank" rel="noopener"><img decoding="async" class="alignleft wp-image-5284" src="https://www.mpeurope.org/wp-content/uploads/2021/06/Covid19-report.png" alt="Cover_MPE COVID-19 report" width="160" height="227" /></a></p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p> Click <strong><a href="https://www.mpeurope.org/wp-content/uploads/2024/04/COVID-19-report-2021_web-1.pdf">here</a></strong> to read or download the full report.</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>The post <a href="https://www.mpeurope.org/impact-of-the-covid-19-pandemic-on-the-healthcare-and-lives-of-myeloma-or-al-amyloidosis-patients-and-their-caregivers/">Impact of the COVID-19 pandemic on the healthcare and lives of myeloma or AL amyloidosis patients and their caregivers</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/impact-of-the-covid-19-pandemic-on-the-healthcare-and-lives-of-myeloma-or-al-amyloidosis-patients-and-their-caregivers/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Generating recommendations for patient- reported outcome (PRO): SISAQOL-IMI</title>
		<link>https://www.mpeurope.org/generating-recommendations-for-patient-reported-outcome-pro-sisaqol-imi/</link>
					<comments>https://www.mpeurope.org/generating-recommendations-for-patient-reported-outcome-pro-sisaqol-imi/#respond</comments>
		
		<dc:creator><![CDATA[Ana Vallejo]]></dc:creator>
		<pubDate>Thu, 18 Feb 2021 13:41:39 +0000</pubDate>
				<category><![CDATA[MPE]]></category>
		<category><![CDATA[Patient evidence]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/generating-recommendations-for-patient-reported-outcome-pro-sisaqol-imi/</guid>

					<description><![CDATA[<p>The post <a href="https://www.mpeurope.org/generating-recommendations-for-patient-reported-outcome-pro-sisaqol-imi/">Generating recommendations for patient- reported outcome (PRO): SISAQOL-IMI</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>&nbsp;</p>
<p>An international multidisciplinary consortium, guided by the European Organisation for Research and Treatment of Cancer (EORTC), has been convened to generate recommendations to standardize the use, analysis, and interpretation of PRO data in cancer clinical trials. <strong>Myeloma Patients Europe (MPE)</strong> is one of the partners in this project representing the <strong>Workgroup or European Cancer Patient Advocacy Networks (WECAN).</strong><span id="more-4716"></span></p>
&nbsp;
<h5><strong>Background</strong></h5>
<p>Measures of health-related quality of life (HRQoL) and other patient-reported outcomes (PRO) generate important data in cancer trials to assist in evaluating the risks and benefits of cancer therapies, and fostering patient-centred care. However, the various ways that these tools are used, analysed and interpreted make it difficult to compare PRO findings across trials. This lack of consensus hinders the application of research findings to inform publications, product labelling, clinical guidelines, and health policy. SISAQOL will work to close these knowledge gaps and create international recommendations on how to analyse PRO data in clinical trials. It is hoped that guidelines and tools emerging from the project will facilitate the analysis of PRO outcomes and result in more reliable findings, improved interpretability, and faster dissemination of data that stem from a higher quality use of statistical methods.</p>
&nbsp;
<h5><strong>Public – private collaborative research</strong></h5>
<p>The SISAQOL consortium is comprised of leading researchers and statisticians, key individuals from various international oncologic and medical societies, advisory and regulatory bodies, academic societies, pharmaceutical industry, cancer institutes and crucially patient advocacy organizations (represented by the Workgroup for European Cancer Patient Advocacy Networks and led by Myeloma Patients Europe) &#8211; with 41 stakeholder groups involved in the project.</p>
<p>This project and its generated recommendations will be of critical importance to organisations like the European Medicines Agency (EMA) and the Food and Drug Administration (FDA), as PRO data presented uniformly across trials and cancers will help support fair and informed decision making. Robust and meaningful PRO data may also lead to improved shared decision-making between patients and their treating physicians. This in turn may lead to improved patient satisfaction, an increased likelihood of adherence to treatment, higher likelihood of treatment success, and a reduction in health‐care cost.</p>
&nbsp;
<h5><strong>Project Outcomes</strong></h5>
<p>This four year collaborative project will develop a set of standards for the design, analysis, interpretation, and presentation of Patient Reported Outcome (PRO) data for cancer clinical trials. Setting International Standards of Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials – Innovative Medicines Initiative (SISAQOL) is a public-private collaborative research project under the Innovative Medicines Initiative (IMI).</p>
<p>The post <a href="https://www.mpeurope.org/generating-recommendations-for-patient-reported-outcome-pro-sisaqol-imi/">Generating recommendations for patient- reported outcome (PRO): SISAQOL-IMI</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/generating-recommendations-for-patient-reported-outcome-pro-sisaqol-imi/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Watch the webinar on Evidence-Based Patient Advocacy</title>
		<link>https://www.mpeurope.org/watch-the-webinar-on-evidence-based-patient-advocacy/</link>
					<comments>https://www.mpeurope.org/watch-the-webinar-on-evidence-based-patient-advocacy/#respond</comments>
		
		<dc:creator><![CDATA[Ana Vallejo]]></dc:creator>
		<pubDate>Thu, 19 Nov 2020 08:38:18 +0000</pubDate>
				<category><![CDATA[MPE]]></category>
		<category><![CDATA[Patient evidence]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/watch-the-webinar-on-evidence-based-patient-advocacy/</guid>

					<description><![CDATA[<p>The post <a href="https://www.mpeurope.org/watch-the-webinar-on-evidence-based-patient-advocacy/">Watch the webinar on Evidence-Based Patient Advocacy</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>&nbsp;</p>



<p>Myeloma Patients Europe (MPE), in collaboration with the <a href="https://www.europeancancer.org/summit#extra-1" target="_blank" rel="noopener noreferrer">European Cancer Organisation’s</a> Patient Advisory Committee, held a <strong>webinar on Evidence-Based Patient Advocacy</strong> on 17 November.<span id="more-4084"></span></p>
<p>This webinar is included in the <strong>MPE Advocate Development Programme (ADP)</strong> and was given by Jan Geissler, member of the European Cancer Organisation’s Patient Advisory Committee and founder and CEO of Patvocates.</p>
<p>&nbsp;</p>
<p>[embedyt] https://www.youtube.com/watch?v=gKFM9bKZM5o&amp;width=550&amp;height=309&amp;iv_load_policy=3&amp;centervid=1&amp;rel=0[/embedyt]</p>
<p>&nbsp;</p>
<p>You can download the slides of this webinar <a href="https://www.mpeurope.org/wp-content/uploads/2020/11/Session-1-Evidence-Based-Patient-Advocacy.pdf">here.</a></p>
<p>The post <a href="https://www.mpeurope.org/watch-the-webinar-on-evidence-based-patient-advocacy/">Watch the webinar on Evidence-Based Patient Advocacy</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/watch-the-webinar-on-evidence-based-patient-advocacy/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Register now for MPE’s webinar on Evidence-Based Patient Advocacy</title>
		<link>https://www.mpeurope.org/register-now-for-mpes-webinar-on-evidence-based-patient-advocacy/</link>
					<comments>https://www.mpeurope.org/register-now-for-mpes-webinar-on-evidence-based-patient-advocacy/#respond</comments>
		
		<dc:creator><![CDATA[Ana Vallejo]]></dc:creator>
		<pubDate>Mon, 19 Oct 2020 07:48:07 +0000</pubDate>
				<category><![CDATA[MPE]]></category>
		<category><![CDATA[Patient evidence]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/register-now-for-mpes-webinar-on-evidence-based-patient-advocacy/</guid>

					<description><![CDATA[<p>The post <a href="https://www.mpeurope.org/register-now-for-mpes-webinar-on-evidence-based-patient-advocacy/">Register now for MPE’s webinar on Evidence-Based Patient Advocacy</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>&nbsp;</p>
<p>Myeloma Patients Europe (MPE), in collaboration with the European Cancer Organisation’s Patient Advisory Committee, will hold a webinar on Evidence-Based Patient Advocacy on Tuesday, 17 November from 14:00 – 17:15 CET.<br /><span id="more-3798"></span><br />This webinar is included in the MPE <a href="https://www.mpeurope.org/what-we-do/capacity-building-advocacy/advocate-development-programme/"><strong>Advocate Development Programme (ADP)</strong></a> and will be given by Jan Geissler, member of the European Cancer Organisation’s Patient Advisory Committee and founder and CEO of Patvocates. Join us to learn more about the importance of evidence-based advocacy and the practical applications of using patient data. The lecture includes 2 sessions:<br /><br /><strong>Session 1: Evidence-Based Patient Advocacy</strong><br />Tuesday, 17 November from 14:00 – 15:30 CET<br /><br />Objectives:</p>
<ul>
<li>The importance of evidence and evidence-based advocacy</li>
<li>Different applications for patient data and evidence</li>
<li>Data that may assist patient advocacy in medicines development and regulatory decisions</li>
<li>Practical examples of the utility of patient-generated evidence in advocacy</li>
</ul>
<p><br /><strong>Session 2: Applying Evidence-Based Patient Advocacy to European Cancer Organisation Summit 2020</strong><br />Tuesday, 17 November from 15:45 – 17:15 CET<br /><br />Objectives:</p>
<ul>
<li>Applying the concepts learned in Session 1: What role could evidence play in the discussions of the European Cancer Organisation Summit 2020 sessions? <a href="https://www.europeancancer.org/summit#extra-1">Click here to learn more about the Summit topics and programme</a>.</li>
</ul>
<p><br />Registration is free of charge. Space is limited, sign up now!</p>
<p>&nbsp;</p>
<p style="text-align: center;"><a href="https://mpeurope-org.zoom.us/webinar/register/WN_a6hHFw6WQoOCkuQkH1tIOA" target="_blank" rel="noopener noreferrer"><img decoding="async" class="alignnone wp-image-907 size-full" src="https://www.mpeurope.org/wp-content/uploads/2017/12/Join-this-webinar.png" alt="" width="256" height="73" /></a></p>
<p>&nbsp;</p>
<h5><strong>Register to attend the European Cancer Summit 2020 </strong></h5>
<p>Every year, the European Cancer Organisation brings together leading oncology specialists, patient advocates, politicians and policy-makers to discuss the main issues impacting cancer policy, for the benefit of citizens, cancer patients and healthcare professionals across Europe.</p>
<p>The European Cancer Summit 2020 will include sessions on the EU Cancer Mission, Europe’s Beating Cancer Plan; the Impact of COVID-19 on Cancer, among others</p>
<p>This year, the <strong>European Cancer Summit 2020</strong> will take place on <strong>November 18 – 19 as a virtual congress.</strong> To help support our members in their ongoing education and advocacy, MPE will be sponsoring <strong>one representative from each member organisation</strong> to attend this Summit as a patient advocate. MPE is offering 5 registrations on a first-come, first-served basis.</p>
<p>We want to ensure that all interested organizations are able to participate in the congress regardless of ability to pay.</p>
<p>In order to be sponsored (MPE members only), follow the steps below:</p>
<ul>
<li>First pre-register as a patient advocate here: <a href="https://www.europeancancer.org/summit#registration=">European Cancer Organisation 2020</a></li>
<li>Then, send the name of your representative and your organization to our Communications Manager, Ana Vallejo, at <a href="mailto:vallejo@mpeurope.org">vallejo@mpeurope.org.</a></li>
<li>After you preregister, you will receive additional information from the European Cancer Summit 2020 with instructions on how to pay the registration fee. Once you have paid the registration fee, please send us your proof of payment along with the MPE reimbursement form.</li>
</ul>
<p><strong>Finally, you must preregister for the patient advocate rate (1<u>50 Euro) </u></strong>.  </p>
<p>&nbsp;</p>
<h5><strong>Applications now open for the MPE Advocate Development Programme (ADP)</strong></h5>
<p>The MPE <a href="https://www.mpeurope.org/what-we-do/capacity-building-advocacy/advocate-development-programme/"><strong>Advocate Development Programme (ADP)</strong></a> is <strong>a 12-month training programme</strong> designed to develop participants’ advocacy knowledge and skills to better serve patients locally, nationally, and across Europe.</p>
<p>Each year 5 to 10 advocates from different countries join the ADP to improve their understanding of clinical research and development, mechanisms of accessing diagnostics and drugs, interaction with stakeholders including clinicians and industry, and the basics of evidence-based advocacy. In addition to monthly sessions, the programme includes <strong>participation in important myeloma scientific meetings in Europe</strong> (with travel and accommodation covered by MPE) such as the European Haematology Association (EHA) Annual Meeting and the European Cancer Summit.</p>
<p><strong>The call for expression of interest to join the MPE ADP 2021 is open.</strong> Find more information <a href="https://www.mpeurope.org/what-we-do/programmes/mpe-advocate-development-programme/">here</a> and submit your application before October 31, 2020.</p>
<p>&nbsp;</p>
<p>The post <a href="https://www.mpeurope.org/register-now-for-mpes-webinar-on-evidence-based-patient-advocacy/">Register now for MPE’s webinar on Evidence-Based Patient Advocacy</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/register-now-for-mpes-webinar-on-evidence-based-patient-advocacy/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Results of MPE members participation in EMA survey on bortezomib</title>
		<link>https://www.mpeurope.org/results-of-the-mpe-members-participation-in-ema-survey-on-bortezomib/</link>
					<comments>https://www.mpeurope.org/results-of-the-mpe-members-participation-in-ema-survey-on-bortezomib/#respond</comments>
		
		<dc:creator><![CDATA[Ana Vallejo]]></dc:creator>
		<pubDate>Fri, 03 May 2019 09:18:25 +0000</pubDate>
				<category><![CDATA[MPE]]></category>
		<category><![CDATA[Myeloma]]></category>
		<category><![CDATA[Patient evidence]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/results-of-the-mpe-members-participation-in-ema-survey-on-bortezomib/</guid>

					<description><![CDATA[<p>As bortezomib, an anti-myeloma medicine, is licensed as both an intravenous (IV – through the vein via a drip) and subcutaneous medicine (through the skin, via an injection), the European Medicines Agency (EMA) recently conducted a survey to understand which method was most commonly used across Europe. They also asked about the location of administration&#8230;</p>
<p>The post <a href="https://www.mpeurope.org/results-of-the-mpe-members-participation-in-ema-survey-on-bortezomib/">Results of MPE members participation in EMA survey on bortezomib</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><img loading="lazy" decoding="async" class="alignright  wp-image-1949" src="https://www.mpeurope.org/wp-content/uploads/2019/05/The-European-Medicines-Agency-EMA-logo.jpg" alt="" width="235" height="193" /></p>
<p>As bortezomib, an anti-myeloma medicine, is licensed as both an intravenous (IV – through the vein via a drip) and subcutaneous medicine (through the skin, via an injection), the <a href="https://www.ema.europa.eu/en" target="_blank" rel="noopener">European Medicines Agency (EMA)</a> recently conducted a survey to understand which method was most commonly used across Europe. They also asked about the location of administration (i.e. at home or in hospital) for patients.</p>
<p><span id="more-1941"></span></p>
<p>The survey was disseminated amongst members of Myeloma Patients Europe (MPE) and received 24 responses from patient advocates in 16 European countries. A big thank you to all members who participated in the survey.</p>
<p>The survey results highlighted the following information:</p>
<ul>
<li>Subcutaneous administration of bortezomib, in an outpatient hospital setting, was the most commonly cited method and location of administration</li>
<li>In most countries , patient advocates (21 out of 24 respondents) understood that bortezomib was administered subcutaneously to patients</li>
<li>In one country, it was understood that bortezomib was prescribed solely in IV format; in another it was administered using both IV and subcutaneous format; and one other country specified that subcutaneous bortezomib was only available for patients over 70 years of age presenting with certain side-effects</li>
<li>In all countries involved in the survey, bortezomib was primarily administered in a hospital setting (either as an outpatient or inpatient) rather than at home. However, one patient advocate outlined a pilot in their country where bortezomib was administered at home</li>
</ul>
<p>The EMA also ran a similar survey with European healthcare professionals (HCPs), which confirmed the findings from the patient advocate survey.</p>
<p>&nbsp;</p>
<h5><strong>Next steps</strong></h5>
<p>The EMA provided feedback that the response to survey was very useful to their work.</p>
<p>The survey was developed by the EMA Committee for Orphan Medicinal Products (COMP), the committee responsible for providing and maintaining orphan designation for new medicines. Orphan designation is where a medicine is considered to address a rare disease or condition and the developer can therefore benefit from a range of incentives to bring their medicine to market (such as protocol assistance and longer marketing exclusivity).</p>
<p>As such, the results of the survey will be considered by each member of the COMP committee in an upcoming opinion  on a myeloma product. The COMP opinion  will be made available in the coming months. They will also be able to use the results of the survey in future myeloma-medicine assessments, where relevant.</p>
<p>&nbsp;</p>
<h5><strong>From IV to subcutaneous administration </strong></h5>
<p>The results of this survey are very interesting to MPE and our members.</p>
<p>Up until 2014, bortezomib was prescribed and administered using an IV drip. Whilst bortezomib was very effective for treating myeloma, patients experienced certain side-effects including peripheral neuropathy – which is mild to severe tingling/burning in hands and feet. Patients reported that this is a very difficult side-effect to live with, impacting on quality of life.</p>
<p>In 2014, a clinical trial showed that when patients received subcutaneous bortezomib, the incidence of neuropathy reduced significantly, as did other side-effects. Subcutaneous bortezomib was found to also be quicker to administer, reducing hospital time for the patient.</p>
<p>Since then, bortezomib was licensed by the EMA as a subcutaneous treatment and is routinely used in this format in clinical trials. It is therefore interesting and positive to see that the majority patient advocates and doctors report that this method of administration has filtered down throughout Europe to patients. It is also helpful to see where the gaps are, so MPE can work with specific members to identify and address them.</p>
<p>If you need any further information or have any questions about the survey or the role of the EMA, please email Policy and Public Affairs Manager Kate Morgan at <a href="mailto:morgan@mpeurope.org">morgan@mpeurope.org</a></p>
<p><strong><em>The European Medicines Agency and the Committee for Orphan Medicinal Products (COMP) would like to thank MPE and its members for their valuable contributions to this survey.</em></strong></p>
<p>The post <a href="https://www.mpeurope.org/results-of-the-mpe-members-participation-in-ema-survey-on-bortezomib/">Results of MPE members participation in EMA survey on bortezomib</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/results-of-the-mpe-members-participation-in-ema-survey-on-bortezomib/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Myeloma patient survey to inform development of personalised medicine tool</title>
		<link>https://www.mpeurope.org/myeloma-patient-survey-inform-development-personalised-medicine-tool/</link>
					<comments>https://www.mpeurope.org/myeloma-patient-survey-inform-development-personalised-medicine-tool/#respond</comments>
		
		<dc:creator><![CDATA[Ana Vallejo]]></dc:creator>
		<pubDate>Mon, 26 Mar 2018 11:08:55 +0000</pubDate>
				<category><![CDATA[MPE]]></category>
		<category><![CDATA[Myeloma]]></category>
		<category><![CDATA[Patient evidence]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/myeloma-patient-survey-inform-development-personalised-medicine-tool/</guid>

					<description><![CDATA[<p>Myeloma Patients Europe (MPE) is running a survey for European myeloma patients to understand their quality of life and how this is impacted by treatment side-effects. The survey is designed to inform Horizon 2020 MMPredict, a project consortium developing a personalised medicines tool to predict the most effective treatment strategy for patients based on their&#8230;</p>
<p>The post <a href="https://www.mpeurope.org/myeloma-patient-survey-inform-development-personalised-medicine-tool/">Myeloma patient survey to inform development of personalised medicine tool</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Myeloma Patients Europe (MPE) is running a survey for European myeloma patients to understand their quality of life and how this is impacted by treatment side-effects.</p>
<p><span id="more-1112"></span></p>
<p>The survey is designed to inform <a href="https://www.mpeurope.org/what-we-do/projects/european-commission-projects-horizon-2020/"><strong>Horizon 2020</strong></a> MMPredict, a project consortium developing a personalised medicines tool to predict the most effective treatment strategy for patients based on their genetic profile.</p>
<p>You can read an English Q&amp;A about MMPredict <a href="https://www.mpeurope.org/what-we-do/publications/qa-horizon-2020-mmpredict/" target="_blank" rel="noopener">here.</a></p>
<p>The Q&amp;A is also available in German. You can read it <a href="https://www.mpeurope.org/what-we-do/publications/fa-fragen-und-antworten-zu-horizont-2020-mmpredict/" target="_blank" rel="noopener" data-cke-saved-href="http://www.mpeurope.org/what-we-do/publications/fa-fragen-und-antworten-zu-horizont-2020-mmpredict/">here.</a></p>
<p>If you are a myeloma patient, we would be grateful if you would take the time to complete the survey through one of the following links:</p>
<table style="border-width: 0px; height: 19px;" width="445">
<tbody>
<tr style="border-width: 0px;">
<td style="border-width: 0px; vertical-align: top; width: 29.05px;"><img loading="lazy" decoding="async" class="alignnone wp-image-1049 " src="http://www.mpeurope.org/wp-content/uploads/2018/03/United-Kingdom.png" alt="" width="25" height="16" /></td>
<td style="border-width: 0px; width: 405.95px;">HORIZON 2020 &#8211; <a href="https://www.surveymonkey.co.uk/r/mmH2020English" target="_blank" rel="noopener">Myeloma Patient Questionnaire</a></td>
</tr>
</tbody>
</table>
<table style="border-width: 0px;">
<tbody>
<tr style="border-width: 0px;">
<td style="border-width: 0px;"><img loading="lazy" decoding="async" class="alignnone wp-image-1052 " src="http://www.mpeurope.org/wp-content/uploads/2018/03/France.png" alt="" width="24" height="16" /></td>
<td style="border-width: 0px;">HORIZON 2020 &#8211; <a href="https://www.surveymonkey.co.uk/r/mmH2020French" target="_blank" rel="noopener">Questionnaire Patient Myélome Multiple</a></td>
</tr>
</tbody>
</table>
<table style="border-width: 0px;">
<tbody>
<tr style="border-width: 0px;">
<td style="border-width: 0px;"><img loading="lazy" decoding="async" class="alignnone wp-image-1048" src="http://www.mpeurope.org/wp-content/uploads/2018/03/bandera-italia-300x180.jpg" alt="" width="24" height="14" /></td>
<td style="border-width: 0px;">HORIZON 2020 &#8211; <a href="https://www.surveymonkey.co.uk/r/mmH2020Italian" target="_blank" rel="noopener">Questionario per pazienti con mieloma multiplo</a></td>
</tr>
</tbody>
</table>
<table style="border-width: 0px;">
<tbody>
<tr style="border-width: 0px;">
<td style="border-width: 0px;"><img loading="lazy" decoding="async" class="alignnone wp-image-1051 " src="http://www.mpeurope.org/wp-content/uploads/2018/03/Germany.png" alt="" width="24" height="16" /></td>
<td style="border-width: 0px;">HORIZON 2020 &#8211; <a href="https://www.surveymonkey.co.uk/r/mmH2020German" target="_blank" rel="noopener">Fragebogen für Patienten mit multiplem Myelom</a></td>
</tr>
</tbody>
</table>
<table style="border-width: 0px;">
<tbody>
<tr style="border-width: 0px;">
<td style="border-width: 0px;"><img loading="lazy" decoding="async" class="alignnone wp-image-1050 " src="http://www.mpeurope.org/wp-content/uploads/2018/03/Netherlands.png" alt="" width="24" height="16" /></td>
<td style="border-width: 0px;">HORIZON 2020 &#8211; <a href="https://www.surveymonkey.co.uk/r/mmH2020Dutch" target="_blank" rel="noopener">Vragenlijst voor Multipel Myeloompatiënten</a></td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
<p><strong>We welcome responses from myeloma patients from <u>any European country.</u></strong> The survey will take an estimated 20 minutes to complete.</p>
<p>&nbsp;</p>
<h4><strong>How will the results be used?</strong></h4>
<p>The results of the survey will be used to develop the outcomes of MMpredict. By combining the responses of all participating patients, the aim is to have a better understanding of the most relevant quality of life issues for patients and relate these to specific treatments or disease characteristics. This will provide valuable insights to help the project consortium understand the kind of personalised medicine tool that could be valuable for patients and their doctors when choosing treatments.</p>
<p>Responses to the survey will remain confidential and will only be used within the context of the research.</p>
<p>&nbsp;</p>
<h4><strong>Where can I find more information?</strong></h4>
<p>If you have any questions about the survey, please email <a href="mailto:morgan@mpeurope.org">morgan@mpeurope.org</a></p>
<p>You can see the MMPredict website here: <a href="https://www.mmh2020.eu">www.mmh2020.eu</a></p>
<p>On behalf of the project consortium, many thanks for your help.</p>
<p>&nbsp;</p>
<p><img loading="lazy" decoding="async" class="alignleft wp-image-963 size-full" src="http://www.mpeurope.org/wp-content/uploads/2018/01/logos-H2020-mmpredict.png" alt="" width="631" height="70" /></p>
<p>&nbsp;</p>
<p><img loading="lazy" decoding="async" class="size-medium wp-image-964 aligncenter" src="http://www.mpeurope.org/wp-content/uploads/2018/01/EC-H2020-300x47.png" alt="" width="300" height="47" /></p>
<p>&nbsp;</p>
<p>The post <a href="https://www.mpeurope.org/myeloma-patient-survey-inform-development-personalised-medicine-tool/">Myeloma patient survey to inform development of personalised medicine tool</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/myeloma-patient-survey-inform-development-personalised-medicine-tool/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Patients and cancer experts launch a joint vision for improving cancer outcomes in Europe</title>
		<link>https://www.mpeurope.org/patients-and-cancer-experts-launch-a-joint-vision-for-improving-cancer-outcomes-in-europe/</link>
					<comments>https://www.mpeurope.org/patients-and-cancer-experts-launch-a-joint-vision-for-improving-cancer-outcomes-in-europe/#respond</comments>
		
		<dc:creator><![CDATA[Ana Vallejo]]></dc:creator>
		<pubDate>Thu, 12 Jan 2017 14:01:52 +0000</pubDate>
				<category><![CDATA[Myeloma]]></category>
		<category><![CDATA[Patient evidence]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/patients-and-cancer-experts-launch-a-joint-vision-for-improving-cancer-outcomes-in-europe/</guid>

					<description><![CDATA[<p>A coalition of 60 patient advocates, healthcare professionals and scientists (including 3 Nobel Prize winners) from 20 European countries have come together to publish a blueprint for improving cancer outcomes and achieving better quality of life for cancer survivors throughout Europe.1 They are members of the European Cancer Concord (ECC®), an equal partnership between patients&#8230;</p>
<p>The post <a href="https://www.mpeurope.org/patients-and-cancer-experts-launch-a-joint-vision-for-improving-cancer-outcomes-in-europe/">Patients and cancer experts launch a joint vision for improving cancer outcomes in Europe</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><a href="https://www.mpeurope.org/wp-content/uploads/2017/01/ecc_.png"><img loading="lazy" decoding="async" class="alignleft wp-image-1744" src="http://www.mpeurope.org/wp-content/uploads/2017/01/ecc_-300x104.png" alt="ecc_" width="300" height="104" /></a>A coalition of 60 patient advocates, healthcare professionals and scientists (including 3 Nobel Prize winners) from 20 European countries have come together to publish a blueprint for improving cancer outcomes and achieving better quality of life for cancer survivors throughout Europe.<sup>1</sup> They are members of the European Cancer Concord (ECC<sup>®</sup>), an equal partnership between patients and cancer experts which launched the European Cancer Patient’s Bill of Rights on World Cancer Day 2014 in the European Parliament in Strasbourg. The publication, in the open access journal ESMO Open, has an ambitious aim &#8211; to increase the long term survival of European citizens with cancer to 70% by 2035. This 70:35 Vision emphasises the need for European countries to share best practice for the benefit of patients.<span id="more-80"></span></p>
<p>The challenge is to ensure that this Vision is achieved in all European countries; this will require investment at national and at European levels, as was envisaged by European Health Ministers through the Vilnius Declaration, in order to ensure that all countries, not just the wealthy ones, achieve the 70:35 Vision, even in this time of economic austerity.</p>
<p><i>“We believe that our Vision 70:35 can deliver real benefit for patients, if we work together in a collaborative way, </i>said <strong>Prof Peter Selby, University of Leeds and President of ECC.</strong><i> “The document is the product of the work of a large group of collaborators and ECC is partnering with many pan European Organisations including the European Cancer Organisation (ECCO), the European Cancer Patient Coalition (ECPC), the European Society for Medical Oncology (ESMO), the European Organisation for the Research and Treatment of Cancer (EORTC) the European Society of Surgical Oncology (ESSO) and the European Cancer Leagues (ECL), in order to achieve this ambitious target”.</i></p>
<p>Sharing best practice and implementing these findings across Europe will underpin improvements in cancer control and cancer care. However, in order to achieve the 70:35 Vision, it is also essential to increase the intensity of research and innovation in Europe and facilitate the rapid translation of discovery science into clinical practice</p>
<p><i>&#8220;Vision 70:35<b> </b>emphasises the scale of our ambition&#8221;, </i>said first author of the paper <strong>Prof Mark Lawler, Queen’s University Belfast and Vice President ECC.</strong> <i>&#8220;We believe that this target is achievable, provided we share best practice and promote innovation and research across European nations and regions. We need to compete, not against each other, but against our common enemy &#8211; Cancer&#8221;. </i></p>
<p>A key component of the vision is the importance of engaging all relevant stakeholders, with cancer patients and their carers working together with a wide range of healthcare and life science professionals, from primary care experts to molecular scientists, all focussed on a common goal, improved outcomes and better quality of life for European citizens</p>
<p><i> “We are delighted to be publishing this initiative that has the potential to benefit so many patients in Europe,” </i>said <strong>Prof Ian Banks, Vice-President of ECC, Chair of the Patient Advocacy Committee ECCO and President of the European Men’s Health Forum (EMHF).</strong> <i>“Involving all stakeholders, including primary care professionals, can significantly improve our chances of success.”</i></p>
<p>“<i>This will help to address a major area of unmet need for European citizens”</i> said <strong>Prof Sarper Diler, Executive Committee Member of ECC, Board Member of Lymphoma Coalition and former president of Myeloma Patients Europe.</strong> “<i>However, there is still a lot of collaborative work to be done to ensure that the </i><i>European Cancer Patient’s Bill of Rights finds real implications in daily practise across Europe</i>.<i> </i></p>
<p>Check the full document <a title="The European Cancer Patient’s Bill of Rights, update and implementation 2016" href="https://www.mpeurope.org/download/1740/" target="_blank" rel="noopener">here.</a></p>
<p><sup><sup>1</sup>Lawler M, Banks I, Law K, et al. The European Cancer Patient’s Bill of Rights, update and implementation 2016. ESMO Open 2016;1:e000127. doi:10.1136/ esmoopen-2016-000127</sup></p>
<p>The post <a href="https://www.mpeurope.org/patients-and-cancer-experts-launch-a-joint-vision-for-improving-cancer-outcomes-in-europe/">Patients and cancer experts launch a joint vision for improving cancer outcomes in Europe</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/patients-and-cancer-experts-launch-a-joint-vision-for-improving-cancer-outcomes-in-europe/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>
